The success of recent tests related to HIV drug has offered a hope of development of a successful HIV medication. The scientists at Tuberculosis Research Centre (TRC) conducted clinical trials for a vaccine to prevent AIDS.

The researchers at TRC have reported success during the fist phase of the tests for new medication. These medical trails are result of efforts of TRC, which is affiliated to the Indian Council of Medical Research (ICMR), the National AIDS Control Organisation (NACO) and the International AIDS Vaccine Initiative (IAVI).

TRC Director V D Ramanathan told media that the present trial was to check the vaccine's safety. Researchers are also aiming to find whether the vaccine fulfilled the secondary objective of stimulating immune response. Mr. Ramanathan added that announcement of the results will done after data analysis.

Dr. Sonali Kochar, Medical Director, IAVI India said that the Phase I trial of an MVA-based AIDS vaccine candidate (TBC-M4) was conducted at the TRC in Chennai.

The preliminary results of the trial showed that the vaccine candidate was generally safe and well-tolerated and the frequency of immune responses by volunteers after three injections was good. The phase-I trial is over, and the final data is under analysis.

The medicine tested in Chennai was designed by a Kolkata-based ICMR scientist. Presently nine MVA vaccine candidates are been tested in various labs around the world.